Research & Innovation 2023

29-30 March

Hinxton Hall Conference Centre, Cambridgeshire

The 2023 ELRIG Research & Innovation conference will discuss how emerging biology and cutting-edge technologies are pioneering the medicines of tomorrow. Bringing together scientists, researchers and entrepreneurs with bold ideas to serve our shared ambitions in creating the next generation of therapeutics to cure more patients around the world. The 2023 R&I meeting will focus on cutting edge innovation, comprising the following four main sessions.

Synthetic biology: genetically programmed healthcare
- - Synthetic biology is enabling drug development by improving the ability of scientists to design and engineer biological systems for specific purposes. These approaches can potentially lead to faster, more efficient, and more cost-effective, sustainable drug development. Furthermore, programmable gene circuits can provide novel functionality and control to therapeutic systems, thereby creating entirely new classes of cell and gene therapies.”
  - Session Chairs: Ron Weiss (Massachusetts Institute of Technology), Simon Todd (AstraZeneca)

Ultra-rare disease drug discovery and personalized therapies
- - With improved (genetic) diagnosis and federated analytics for finding patients, we have come to realize that rare diseases are not so rare after all. Recent developments in drug development, including gene therapy and oligonucleotide therapy approvals are also opening up avenues for personalized or n=1 drugs. Clinical development is furthermore adapting to use biomarkers, single patient experimental medicine and decentralised clinical trials.
  - Session Chairs: David Fischer (Charles River) & Joanne Hackett (IQVIA)

Age-Old Challenges, Modern Solutions: The Role of Geroscience In Addressing Age-Related Diseases
- - Lifespan is increasing but healthy life expectancy is not keeping pace – we are living longer but not healthier. Geroscience aims to treat age-related diseases by addressing core ageing processes; novel drug discovery approaches have the potential to help deliver this objective.
  - Session Chairs: Janet Lord (University of Birmingham), Lynne Cox (Oxford)

The Rise of AI Driven Drug Discovery
- - We are seeing a revolution in the application of AI to improve decision making in drug discovery. This session will focus on presenting and evaluating emerging technologies and innovations in AI which promise to drive drug discovery research in the future.
  - Session Chairs: Garry Pairaudeau (Exscientia) & Kathryn Giblin (AstraZeneca)

ELRIG R&I23 Programme

The poster session at ELRIG events is always full of lively discussions and there were two poster awards up for grabs at Research & Innovation, a general poster award and the best ECP poster award.

The award for the was won by Ganesh Shanane of Iktos entitled “Structure-based generative AI de novo drug design” and the award for the Best ECP Poster was won by Emma Buzzard of the University of Exeter entitled “Cryo-ET for investigating the role of respiratory chain organization in health and disease”.

Congratulations to all our award winners.

Conference Venue:

Hinxton Hall Conference Centre,
Wellcome Genome Campus,
Cambridge,
CB10 1SA

Research & Innovation 2023 accommodation can be booked onsite at Hinxton Hall via this linkHinxton Hall Accommodationor in other areas of Cambridge through our partner Reservation Highway by following this link – www.reservation-highway.co.uk

Tel +44 (0)1423525577
Email: admin@reservation-highway.co.uk
Fax : 01423 525599

ELRIG cannot recommend or endorse any of the hotels offered by Reservation Highway.

Travel information:

Details concerning travelling to site: Getting here – Hinxton Hall
If you are travelling by bicycle, there are dedicated bike racks on site.
The site also offers a free shuttle bus service from Whittlesford Train Station to campus. Shuttle Bus Timetable
There are parking spaces available on site – please email info@elrig.org if you would like a space.

ELRIG is only able to provide suggestions on how delegates may travel to or places they may stay at, to attend its events. However, ELRIG cannot recommend nor endorse any of the travel choices nor hotels that attendees make and is not liable for any of the services that its delegates procure.

An Early Career Professional (ECP) can be a student in undergraduate, PhD or first post-doctoral position or a scientist that is less than 5 years on their industrial career path. These ECPs are critical contributors to ELRIG, bringing new science, fresh ideas and energy to every event.

This award will recognise impact achieved through one of the following ways:

Through the delivery of impactful science, contributing to early, pre-clinical drug discovery
By their science or technology development work
Through their leadership or facilitation of collaborations within the drug-discovery space
Through other philanthropic and volunteering contributions

ECPs may apply directly or be nominated by a colleague, as ELRIG invites the wider community to propose ECP colleagues that have made noteworthy impact. In each case, application requires submission of the following:
1-page, 300-word synopsis of the ECPs contribution and its impact on early drug discovery, using the following form and a brief 2-page resume.

This year’s spring winner, Yichao Yu was presented his award by Del Tresize, ELRIG Board member, at Research & Innovation 2023., in front of the entire audience of over 350 delegates Yichao, is a research associate at University College of London, presented his work which uses magnetic nanoparticles to stimulate astrocytes and the potential application in neuromodulation in conjunction with ultrasound.

PDF PROGRAMME

Our App

ALL OUR EVENT INFORMATION IN
THE PALM OF YOUR HAND

If you plan to attend an ELRIG event download the free ELRIG app and access all our conference information and lecture schedules and more straight from your phone or pad..

Download Now